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Abstract
The optimal duration of dual antiplatelet therapy (DAPT) for stable coronary artery disease and acute coronary syndrome
is a complex decision. We review current literature on standard duration DAPT versus short duration DAPT (6 months
or shorter) or extended duration DAPT (>12 months) after percutaneous coronary intervention with drug-eluting stent
placement, and prolonged treatment after 12 months in acute coronary syndrome. Current guideline recommendations are
summarised, including the use of risk scores for ischaemic and bleeding risk assessment. Because of the limitations of
current risk scores, we propose multiple patient-related and procedure-related factors for the ischaemic and bleeding risk
assessment aiding in personalised DAPT duration.
Keywords DAPT · Short-term · Long-term
Introduction
Dual antiplatelet therapy (DAPT) is directed at preventing
stent thrombosis, myocardial infarction, and stroke and it
is standard therapy after percutaneous coronary interven-
tion (PCI) and after acute coronary syndrome (ACS). In
the Netherlands more than 45,000 patients are treated with
percutaneous coronary intervention each year. In Europe,
it is estimated that approximately 1,400,000 and 2,200,000
patients per year may have an indication for DAPT after
percutaneous coronary intervention or myocardial infarc-
tion, respectively [1].
Colombo et al. introduced a strategy of improved bare-
metal stent (BMS) expansion with high-pressure balloon in-
flation guided by intravascular ultrasound images first [2].
Low rates of stent thrombosis were achieved with the com-
bination of this stent technique and DAPT consisting of
aspirin and 1 month of ticlopidine, and this proved to be
the advent of DAPT as we know it today.
Drug-eluting stents (DES) were subsequently introduced
to mitigate the risk of restenosis. However, concerns over
late and very late stent thrombosis occurring after first-gen-
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eration DES implantation increased the need for long-term
DAPT [3]. However, the risks of late and very late stent
thrombosis have declined considerably since the introduc-
tion of second generation DES [4]. In conjunction with the
results of recent randomised controlled trials (RCTs) that
investigated shorter duration of DAPT, this has led to a rapid
paradigm shift in the way the clinical community perceives
DAPT duration.
Conversely, among patients with acute coronary syn-
drome, the risk of myocardial infarction outside the stented
segment remains high—well beyond 12 months after the
initial procedure [5]. Twenty percent of patients with my-
ocardial infarction who are event free the first year, suf-
fer a major adverse cardiovascular event between 1 and
4 years after their index event [6]. Moreover, among pa-
tients with ST-elevation myocardial infarction (STEMI) the
average daily risk of ischaemia exceeds the average daily
risk of bleeding beyond 12 months after the initial my-
ocardial infarction [7]. Given the overwhelming evidence
that long-term DAPT reduces myocardial infarction out-
side the stented segment as well as stroke, continued DAPT
12 months after the initial myocardial infarction might im-
prove the net clinical outcome.
In light of the above, choosing the optimal DAPT du-
ration has become more complex than ever. The aim of
this manuscript is to provide guidance in determining the
optimal DAPT duration for individual patients.
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KEY MESSAGE
Defining the optimal duration dual antiplatelet therapy for the individual patient requires 
careful assessment of ischemic and hemorrhagic risk.
In patients with a low ischemic risk (such as uncomplicated PCI for stable CAD) or high 
bleeding risk, a short course (3-6 months) dual antiplatelet therapy is reasonable.
In patients with a high ischemic risk and acceptable bleeding risk, extending DAPT might 
improve outcomes.
Risk scores (such as the DAPT score and PRECISE-DAPT score) might be of utility to 
facilitate risk stratification. 
Available evidence
Duration of DAPT in stable coronary artery disease
(CAD)
Based on results of the CHARISMA (Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization, Man-
agement, and Avoidance) study [8], DAPT is currently not
indicated for medically managed patients with stable CAD
and no history of myocardial infarction [9]. However, after
PCI with stent implantation, DAPT is standard practice. To
date, there have been no randomised comparisons of differ-
ent DAPT durations in a dedicated study confined to stable
CAD patients undergoing PCI. Several studies have estab-
lished the 1-month course of DAPT after bare-metal stent
implantation [10–12]. Owing to the increased risk of late
stent thrombosis, an arbitrary minimal 12-month DAPT du-
ration has been subsequently recommended based on expert
opinion after first generation DES, irrespective of clinical
presentation. Therefore, recommendations regarding stable
CAD patients undergoing PCI are based on subgroup anal-
yses from the pivotal RCTs discussed in the following sec-
tion.
Short duration of DAPT (6 months or shorter) after
PCI with DES for stable CAD or ACS
Tab. 1 provides an overview of characteristics and outcomes
of studies comparing different durations DAPT after PCI
with DES. Five RCTs have compared a shorter duration
(3–6 months) DAPT with 12 months DAPT after PCI with
DES for various indications [13–17]. The main endpoints of
these non-inferiority trials were composite ischaemic events
(or a composite of ischaemic and haemorrhagic events) and
stent thrombosis. In these studies, 24–75% of patients pre-
sented with ACS. Nonetheless, most of these studies in-
cluded a study population with a low risk of ischaemic
events. For instance, in EXELLENT (Efficacy of Xience/
Promus Versus Cypher to Reduce Late Loss After Stenting)
and SECURITY (Second-Generation Drug-Eluting Stent
Implantation Followed By Six- Versus Twelve-Month Dual
Antiplatelet Therapy) only biomarker-negative patients with
ACS were included [15, 17]. In OPTIMIZE (Optimized Du-
ration of Clopidogrel Therapy Following Treatment With
the Zotarolimus-Eluting Stent in Real-World Clinical Prac-
tice), STEMI patients were excluded [14]. Moreover, in the
majority of these studies, patients were randomised at the
time of PCI, and not at the time of DAPT discontinuation,
thus including events occurring while both treatment groups
were on DAPT, potentially diluting differences in ischaemic
events arising after DAPT cessation at 3 or 6 months in the
shorter DAPT arm. Therefore, given that these studies were
non-inferiority studies, the study results should be inter-
preted with caution. Finally, non-inferiority margins were
wide in some studies (much wider than would be deemed
clinically relevant differences), inclusion of patients in some
studies terminated prematurely, event rates turned out much
lower than anticipated and, therefore, all of these studies
were underpowered to detect differences in hard clinical
endpoints such as stent thrombosis.
Nonetheless, none of these studies or subsequent meta-
analyses found an increased risk of stent thrombosis or ma-
jor adverse cardiac events (MACE) with a shorter duration
of DAPT. On the contrary, short-duration DAPT was asso-
ciated with fewer bleeding complications [18, 19]. Taken
together, these studies demonstrate that in patients with
a low ischaemic risk or with a high bleeding risk, a shorter
duration of DAPT may be reasonable in patients after un-
complicated elective PCI with second generation DES (e.g.,
everolimus-eluting or zotarolimus-eluting), or patients with
ACS at relatively high bleeding risk.
Extended duration of DAPT (>12 months) after PCI
with DES for stable CAD or ACS
Six RCTs, consisting predominantly of patients treated with
elective DES implantation, compared prolonged DAPT (to-
tal therapy duration: 18–48 months) with 6–12 months
of DAPT (Tab. 1; [20–25]). Four of these studies were
underpowered to detect differences in major endpoints. In
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Table 1 Studies comparing different durations of dual antiplatelet therapy after PCI
Study (year) Randomi-
sation
Sample
size
Primary end-
point
Design and
randomisation
% ACS Proportion
with Newer-
Generation
DES (%)
Primary endpoint (short vs.
long DAPT)
RESET (2012)
[13]
3 vs.
12 months
DAPT
2,117 Cardiac
death, MI,
ST, revasc. or
bleeding
Non-inferiority
Randomisation
at time of PCI
55 85 4.7% in both arms (pNI
<0.001)
OPTIMIZE
(2014) [14]
3 vs.
12 months
DAPT
3,119 NACCE—death,
MI, stroke, or
bleed
Non-inferiority
Randomisation
at time of PCI
32 100 6.0% with 3 months DAPT
vs. 5.8% with 1-year DAPT
(pNI = 0.002)
EXCELLENT
(2011) [15]
6 vs.
12 months
DAPT
1,443 Cardiac
Death, MI,
or ischemia
driven TVR
Non-inferiority
Randomisation
at time of PCI
51 75 4.8% with 6-months
vs. 4.3% with 1-year DAPT
(pNI = 0.001)
ISAR-SAFE
(2014) [16]
6 vs.
12 months
DAPT
4,000*
(planned:
6,000)
Death, MI,
stroke, or
TIMI major
bleed
Non-inferiority
Randomisation
at DAPT discon-
tinuation
40 72 1.5% with 6 months DAPT
vs. 1.6% with 1-year DAPT
(pNI < 0.001)
SECURITY
(2014) [17]
6 vs.
12 months
DAPT
1,399*
(planned:
2,740)
Cardiac
death, MI,
ST, or stroke
Non-inferiority
Randomisation
at time of PCI
38 100 4.5% with 6-months DAPT
vs. 5.7% with 1-year DAPT
(pNI  0.05)
PRODIGY
(2012) [20]
6 vs.
24 months
DAPT
1,970 Death, MI,
stroke
Superiority
Randomisation
1 month after
PCI
75 50 10.0% with 6 months DAPT
vs. 10.1% with 2-year DAPT
(p= 0.91)
ITALIC (2014)
[21]
6 vs.
24 months
DAPT
1,822*
(planned:
2,475)
Death, MI,
urgent TVR,
stroke or
bleeding
Non-inferiority
Randomisation
at time of PCI
24 100 1.6% with 6 months DAPT
vs. 1.5% with 2-year DAPT
ARCTIC Inter-
ruption (2014)
[22]
12 vs.
18–
24 months
1,259 Death/MI/ST/
CVA/TVR
Superiority
Randomisation
at DAPT discon-
tinuation
26 63 4.0% in both arms (median
17 months FU) (p= 0.58)
DAPT (2015)
[23]
12 vs.
30 months
9,961 1 ST
2 MACE
Superiority
Randomisation
at DAPT discon-
tinuation
43 59 ST: 1.4% vs. 0.4% and MACE
4.1 vs. 2.1% (p< 0.001)
DES-LATE
(2010) [24]
12 vs.
36 months
5,045 Cardiac
death/MI/
CVA
Superiority
Randomisation
at DAPT discon-
tinuation
61 30 2.4% SAPT vs. 2.7% DAPT
(p= 0.75)
OPTIDUAL
(2015) [25]
12 vs.
48 months
1,385*
(planned:
1,966)
Death/MI/
CVA/bleeding
Superiority
Randomisation
at DAPT discon-
tinuation
36 59 7.5% SAPT vs. 5.8% DAPT
(p= 0.17)
* Inclusion of patients terminated prematurely
RESET REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation, NI non-inferior,
OPTIMIZE Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice,
EXCELLENT Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting, ISAR-SAFE Intracoronary Stenting and Antithrom-
botic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting, SECURITY Second-Generation Drug-E-
luting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy, PRODIGY Prolonging Dual Antiplatelet Treatment
After Grading Stent-Induced Intimal Hyperplasia Study, ITALIC Is There a Life for DES After Discontinuation of Clopidogrel, ARCTIC Assess-
ment with a double Randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after DES implantation, and (2)
Treatment Interruption versus Continuation, 1 year after stenting, DAPT Dual AntiPlatelet Therapy, DES-LATE Optimal Duration of Clopidogrel
Therapy With DES to Reduce Late Coronary Arterial Thrombotic Event, OPTIDUAL OPTImal DUAL antiplatelet therapy, CVA cerebrovascular
accident, DAPT dual antiplatelet therapy, DES drug-eluting stent, MACE major adverse cardiac event, MI myocardial infarction, NACCE Net Ad-
verse clinical and cerebral event, PCI percutaneous coronary intervention, SAPT single antiplatelet therapy, ST stent thrombosis. TVR target vessel
revascularisation
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ITALIC (Is There a Life for DES After Discontinuation of
Clopidogrel) patients were randomised at the time of PCI
and in PRODIGY (Prolonging Dual Antiplatelet Treatment
After Grading Stent-Induced Intimal Hyperplasia Study)
patients were randomised one month after PCI, potentially
diluting differences in outcome between the two study
groups [20, 21].
In the DAPT (Dual Antiplatelet Therapy) study, patients
who did not suffer a major adverse cardiac event or bleed-
ing in the first year following DES implantation, were ran-
domised to an additional 18 months of DAPT or to aspirin
monotherapy. Extended DAPT was associated with a 0.7%
absolute reduction in stent thrombosis, a 1.6% absolute re-
duction in MACE, and a 0.9% absolute increase in GUSTO
(global use of strategies to open occluded coronary arter-
ies) moderate or severe bleeding [26]. Unexpectedly, there
was a borderline significant increase in overall mortality
(0.5% absolute increase) with prolonged DAPT, which was
the result of a statistically significant increase in non-car-
diovascular mortality, mainly related to increased cancer-
related mortality [27]. This may simply reflect a play of
chance: cancer had been diagnosed prior to enrolment in
nine patients who subsequently died, eight of whom were
randomly allocated to extended DAPT [27].
The meta-analyses conducted after publication of the
DAPT study, demonstrated a reduction in stent thrombo-
sis and myocardial infarction with extended DAPT, but this
did not translate into a reduction in cardiovascular mortality.
In fact, several of these meta-analyses found an increased
risk of non-cardiovascular and all-cause mortality with ex-
tended DAPT after PCI [18, 19, 28]. These meta-analy-
ses, however, did not include the OPTIDUAL (OPTImal
DUAL antiplatelet therapy) study. Moreover, none of the
11 RCTs conducted so far were powered for mortality. In
the systematic review and meta-analysis conducted by the
Evidence Review Committee (ERC) of the American Col-
lege of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines, including the OPTIDUAL
study, no statistically significant difference in mortality was
observed between extended DAPT and short-term DAPT
[29]. However, when trials were stratified into completed
trials or incomplete trials with slow enrolment, there was
weak evidence for increased mortality. A subanalysis from
the DAPT trial shows that this might be explained by pa-
tients with stable CAD [30]. In summary, whether extended
DAPT is associated with excess mortality in patients treated
with PCI remains uncertain and deserves further research.
Duration of dual antiplatelet therapy in ACS
The currently recommended duration of DAPT for patients
with ACS, non-ST-segment elevation ACS (NSTE-ACS) as
well as ST-segment elevation ACS (STE-ACS) is 12 months
[9]. This recommendation is based on the CURE (Clopi-
dogrel in Unstable Angina to Prevent Recurrent Events)
trial, the PLATO (Platelet Inhibition and Patient Outcomes)
study and the TRITON-TIMI 38 (Trial to Assess Improve-
ment in Therapeutic Outcomes by Optimizing Platelet In-
hibition with Prasugrel—Thrombolysis in Myocardial In-
farction 38). In the CURE trial, patients with NSTE-ACS
were randomised to clopidogrel for 3–12 months (median
9 months) or placebo, in addition to aspirin. The majority
of patients were treated without revascularisation, though
a reduction in ischaemic events was observed both in those
treated with revascularisation (PCI or coronary artery by-
pass grafting) and in those treated with medical therapy
alone [31]. In PLATO, treatment with ticagrelor during an
intended 12 months (but actual median 9 months) was asso-
ciated with a reduction in the primary endpoint, cardiovas-
cular death, myocardial infarction, or stroke, as compared
with clopidogrel in patients with NSTE-ACS and STEMI
[32]. In TRITON-TIMI, 38 prasugrel for a median duration
of 14.5 months reduced the primary endpoint cardiovascular
death, myocardial infarction, or stroke, as compared with
clopidogrel in ACS patients undergoing PCI in the setting
of ACS [33].
The results of the CURE trial have been extrapolated
to patients with STEMI on the basis of the fact that in
both NSTE-ACS and STEMI coronary thrombosis is the
final instigating event leading to ischaemia. Based on this
consideration, as well as on the results from the PLATO and
TRITON-TIMI 38 trials, it is recommended that patients
with STEMI are treated with DAPT for 12 months [9].
A shorter duration of DAPT after ACS was investigated
in the studies discussed under section “Short duration of
DAPT (6 months or shorter) after PCI with DES for stable
CAD or ACS”. These studies were, however, not dedicated
ACS studies, and most studies only included low-risk ACS.
In CHANGE DAPT, a single centre, observational study
comparing clopidogrel with ticagrelor in ACS, ticagrelor
was not associated with better outcomes as compared with
clopidogrel. The study was conducted at Thoraxcentrum
Twente, where on 1 May 2014 the use of clopidogrel was re-
placed by ticagrelor. The investigators compared 1,053 pa-
tients treated with ticagrelor with a historical control group
(n= 1,009) treated with clopidogrel before 1 May 2014.
Ticagrelor was not associated with a reduction in MACE,
but it was associated with an increase in major bleeding
[34].
Extended DAPT after history of myocardial
infarction
In the PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients with Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin-Throm-
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bolysis in Myocardial Infarction 54) trial, 21,162 patients
with a history of MI and at least one high-risk feature were
randomised to ticagrelor at a dose of 90mg twice daily,
ticagrelor at a dose of 60mg twice daily, or placebo on top
of aspirin. After a median of 33 months, both doses of tica-
grelor significantly reduced the risk of cardiovascular death,
myocardial infarction, or stroke and increased the risk of
major bleeding. The lowest number to treat and highest
number to harm was observed with the dose of 60mg twice
daily [35]. A subanalysis showed that patients with lower
extremity arterial disease, known to be at greater ischaemic
risk, had a heightened benefit from extended ticagrelor [36].
A meta-analysis including PEGASUS-TIMI 54 and various
subanalyses showed a reduction in cardiovascular death,
myocardial infarction, and stroke with extended DAPT, at
the cost of increased major bleeding [37].
DAPT duration after PCI for complex lesions
Recently 2 studies have been published that investigated
DAPT duration after complex PCI. These studies showed
that complex PCI was an independent predictor of is-
chaemic events in the first year, but not of ischaemic events
beyond 12 months after PCI. In an individual patient pooled
meta-analysis consisting of studies comparing 3–6 months
DAPT with 12–24 months DAPT, 12–24 months DAPT
was associated with significant reductions in MACE com-
pared with 3–6 months DAPT [38]. Conversely, in the
DAPT study among patients without events in the first
12 months, the benefits of extending DAPT beyond one
year were similar in subjects with and without complex
lesions [39]. These findings suggest that complex PCI may
be a more useful discriminator for predicting the benefit
of DAPT within the first year after PCI, but less useful
for predicting benefit of longer durations after 12 months.
However, we have to keep in mind that the DAPT trial
included relatively low-risk patients, and some high-risk
lesions (stent placement with stent diameter <2.25mm or
>4.0mm) were excluded.
The European Society of Cardiology (ESC)
2017 focused update on DAPT
Currently available studies on DAPT duration are somewhat
confusing. On the one hand, studies investigating a short
course DAPT established non-inferiority of 3–6 months
DAPT as compared with 12 months DAPT. On the other
hand, pivotal trials such as the DAPT study and PEGA-
SUS-TIMI 54 study, showed the superiority of extended
DAPT over 12 months DAPT in terms of a reduction in
ischaemic events. How can these contradicting findings be
explained? First, the aforementioned weaknesses in study
design (randomisation at the time of PCI—not at DAPT dis-
continuation, lower than anticipated event rates, wide pre-
specified non-inferiority margins) might have contributed
to type II error in the short-term DAPT trials (e.g. erro-
neously concluding that short-term DAPT is non-inferior to
standard DAPT). Second, short-term DAPT trials included
patients with a low ischaemic risk, whereas superiority of
long term DAPT was predominantly shown in patients with
a high ischaemic risk. This indicates that a short-term DAPT
course might be non-inferior in low-risk patients, but in
high-risk patients extended DAPT might be beneficial. In
line with this interpretation, the recommended duration of
DAPT in the recently published ESC 2017 focused update
on DAPT is dependent on the indication and the throm-
botic and bleeding risk [9]. In patients with stable CAD
undergoing PCI with DES, DAPT with aspirin and clopi-
dogrel is recommended for 6 months [9]. Shorter DAPT for
3 months, might be considered in patients at high bleeding
risk (or 1 month in patients with extremely high bleeding
risk, such as those undergoing non-deferrable surgery with
high bleeding risk). In patients who have tolerated DAPT
without a bleeding complication and who are at low bleed-
ing risk but high thrombotic risk, continuation of DAPT
with clopidogrel for 6–30 months may be considered.
With regards to ACS patients, DAPT consisting of
a P2Y12 inhibitor on top of aspirin is recommended for
12 months. In patients who have a high bleeding risk,
discontinuation of P2Y12 inhibitor therapy after 6 months
should be considered. Continuation of DAPT for longer
than 12 months may be considered if it is tolerated without
any bleeding complications [9].
Alternative antithrombotic therapies for secondary
prevention
Since the introduction of the ESC focused update on DAPT,
several important trials have been published expanding the
antithrombotic therapy options for secondary prevention
in coronary artery disease. With regards to prolonged
antithrombotic treatment in patients with stable angina,
the COMPASS trial evaluated whether rivaroxaban alone
or in combination with aspirin would be more effective
than aspirin alone for secondary cardiovascular prevention.
Around 27,000 patients with stable atherosclerotic disease
were included and followed for a mean duration of two
years. Patients who were assigned to rivaroxaban (2.5mg
twice daily dose) plus aspirin had better cardiovascular
outcomes and more major bleeding events than those as-
signed to aspirin alone. Rivaroxaban (5mg twice daily)
alone did not result in better cardiovascular outcomes than
aspirin alone and resulted in more major bleeding events
[40]. In patients with an indication for prolonged intensive
antithrombotic therapy, the specific combination therapy
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that may be best for reducing the risk of major thrombotic
events is unclear. No data are currently available comparing
prolonged DAPT with the aspirin plus rivaroxaban combi-
nation, and differences in study populations limit a direct
comparison of available evidence.
An alternative treatment option to shorter DAPT in ACS
patients who have a high bleeding risk has been investigated
in the TROPICAL-ACS trial. In this trial, ACS patients who
underwent guided PCI were randomised to de-escalation of
antiplatelet treatment or standard treatment. Because the
greatest anti-ischaemic benefit of potent antiplatelet drugs
over the less potent clopidogrel occurs early, while most
excess bleeding events arise during chronic treatment, the
investigators introduced a de-escalation regimen of DAPT
involving switching from prasugrel to clopidogrel after one
week. This differentiated way of treating ACS patients with
clopidogrel might reduce bleeding risks compared with ex-
tended treatment with a more potent antiplatelet agent such
as prasugrel. However, guided de-escalation of antiplatelet
treatment was non-inferior to standard treatment with pra-
sugrel at 1 year after PCI in terms of net clinical benefit,
and bleeding outcomes were comparable [41].
Both studies investigated new treatment options, and the
major challenge for clinicians, regulatory agencies, guide-
line committees and further studies will be identifying the
patients who will benefit from these novel treatment strate-
gies.
Risk stratification
Taken as a whole, current evidence shows that extended
DAPT is associated with a reduction in ischaemic risk that
is similar in magnitude to the increase in haemorrhagic risk.
In an analysis by the ERC, among DES-treated patients,
extended DAPT was associated with 6 fewer myocardial
infarctions and 3 fewer stent thromboses but 5 additional
major bleeding events per 1,000 patients treated with DAPT
per year [29]. Likewise, the PEGASUS-TIMI 54 study
showed that for every 1,000 patients treated with ticagrelor
60mg twice daily, there were 4 fewer ischaemic events but
3 more major bleeding events per year. Thus, it is clear that
not all patients benefit from prolonged DAPT; patients who
have a high risk of ischaemic events and a relatively low
risk of bleeding events are likely to benefit from prolonged
DAPT. To facilitate risk stratification in order to maximise
ischaemic protection and minimise bleeding risks in the
individual patient risk scores could be useful. The ESC fo-
cused update on DAPT currently states that the use of risk
scores may be considered to evaluate the benefits and risks
of different DAPT durations (Class IIB recommendation)
[9].
The DAPT score is a combined ischaemic and haem-
orrhagic risk score ranging from –2 (high bleeding risk,
low ischaemic risk) to 10 points (high ischaemic risk, low
bleeding risk), including nine risk factors (age, congestive
heart failure/low left ventricular ejection fraction (LVEF),
vein graft stenting, myocardial infarction at presentation,
prior myocardial infarction or PCI, diabetes, stent diame-
ter <3mm, smoking and paclitaxel-eluting stent placement)
[42]. The DAPT score was developed in 11,648 patients
who were enrolled in the DAPT study and it was externally
validated in 8,136 patients enrolled in the PROTECT (Pa-
tient-Related Outcomes With Endeavor vs. Cypher Stent-
ing) trial. It had modest predictive ability for both ischaemic
and bleeding events (c-statistic 0.70 and 0.68 respectively
and 0.64 and 0.64 in the PROTECT dataset), and impor-
tant clinical risk factors for both bleeding (such as previous
bleeding, anaemia, thrombocytopenia, and bleeding diathe-
sis) and ischaemia (multivessel disease, stent length, bifur-
cation stenting) were not included in the risk score. Appli-
cation of the DAPT score in the DAPT study demonstrated
a reduced net adverse clinical events (combination of is-
chaemic and haemorrhagic events) with prolonged DAPT
when compared with a standard course DAPT. Conversely,
in those with a low DAPT score (<2), extended DAPT was
associated with an increase in net adverse events [42]. Thus,
the risk/benefit ratio of prolonged DAPT was favourable
among those with a high DAPT score (≥2), e.g. low bleed-
ing risk, high ischaemic risk. One has to keep in mind
that de DAPT score was developed in a patient population
in which standard versus prolonged DAPT was compared,
and it might not be relevant when choosing between short
and standard DAPT duration.
Recently, the PRECISE-DAPT risk score was developed
and validated retrospectively in large, randomised, patient
cohorts comparing the duration of DAPT [43]. The PRE-
CISE-DAPT-score is a five-item risk score that identifies
patients with a high bleeding risk after ACS, concluding that
longer duration of DAPT significantly increases the bleed-
ing risk in patients with a high PRECISE-DAPT-score.
Conversely, shorter duration of DAPT in patients without
a high bleeding risk increases ischaemic risk in patients
with a low PRECISE-DAPT-score. The novel score was
assessed within patients randomised to different DAPT du-
rations to identify the effect on bleeding and ischaemia of
a long (12–24 months) or short (3–6 months) treatment in
relation to baseline bleeding risk.
Personalised treatment and risk stratification
in daily practice
Determining DAPT duration requires close consideration of
clinical and procedural risk factors for ischaemic events and
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PCI for SCAD
Contraindicaons for DAPT?
Paents meeng ≥ 1 of the following 
criteria:
• Cirrhosis of the liver with 
oesophageal varices
• Explained/unexplained anaemia
• Persistent or recurrent 
thrombocytopenia < 30
• Bleeding diathesis
• Acve malignancy
• Previous major bleeding (related 
to anthromboc treatment)
• Frailty
3 months1
High ischaemic risk?
Paents meeng ≥ 1 of the following 
criteria:
• Vein gra PCI
• Previous stent thrombosis
• Recurrent myocardial infarcon 
(STEMI or NSTEMI) during SAPT 
or DAPT
• Severe, diﬀuse, mulvessel 
disease with no chance of
complete revascularisaon
• Poorly controlled DM (HbA1C ≥ 
53 mmol/L)
• Peripheral artery disease
Extended 
DAPT
No
No
PCI of complex lesion or complicaon of PCI?
Paents meeng ≥1 of the following criteria:
• Bifurcaon stenng (2 stents)
• Stent length >60 mm
• ≥3 stents implanted
• Incomplete apposion
• Residual edge dissection
12 months
6 months
No
Yes
Yes
Yes
ACS
Contraindicaons for DAPT?
Paents meeng ≥ 1 of the following 
criteria:
• Cirrhosis of the liver with 
oesophageal varices
• Explained/unexplained anaemia
• Persistent or recurrent 
thrombocytopenia < 30
• Bleeding diathesis
• Acve malignancy
• Previous major bleeding (related 
to anthromboc treatment)
• Frailty
3 – 6 months1
High ischaemic risk?
Paents meeng ≥ 1 of the following 
criteria:
• Vein gra PCI
• Previous stent thrombosis
• Recurrent myocardial infarcon 
(STEMI or NSTEMI) during SAPT 
or DAPT
• Severe, diﬀuse, mulvessel 
disease with no chance of
complete revascularisaon
• Poorly controlled DM (HbA1C ≥ 
53 mmol/L)
• Peripheral artery disease
Extended 
DAPT
No
No
12 months
Yes
Yes
a b
Fig. 1 a Flowchart illustrating the recommended duration of dual antiplatelet therapy in patients with stable coronary artery disease according
to clinical and procedural risk factors for bleeding and ischaemia. b Flowchart illustrating recommended duration of dual antiplatelet therapy in
patients with acute coronary syndrome (1In patients with an extremely high bleeding risk, such as those scheduled for non-deferrable surgery
with high bleeding risk, a minimum of one month of DAPT is mandatory. ACS acute coronary syndrome, DM diabetes mellitus, DAPT dual
antiplatelet therapy, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, SAPT single antiplatelet
therapy, SCAD stable coronary disease, STEMI ST-segment elevation myocardial infarction)
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bleeding that are not included in the currently available risk
scores. Thus, when using risk scores to guide decisions on
DAPT duration, physicians should bear in mind that the risk
scores are not comprehensive and that a complete analysis
of patient and procedural factors is mandatory to determine
DAPT duration. An important contributing factor in per-
sonalised treatment is the indication for oral anticoagulants.
Extensive research is being performed on this subject, and
recommendations are summarised in the latest ESC DAPT
guidelines [9]. A more comprehensive review is beyond the
scope of this manuscript.
Ultimately, the decision for whom to shorten or continue
DAPT is a complex one and requires close collaboration
between the interventional cardiologist and the cardiolo-
gist at the clinic or outpatient department. Based on coro-
nary anatomy and procedural aspects such as stent length,
stent apposition, and bifurcation stenting, the interventional
cardiologist should provide a recommendation on DAPT
duration. In the end the cardiologist who is the patient’s
case manager is the one responsible for the DAPT dura-
tion considering bleeding risk, the recommendation of the
interventional cardiologist, risk scores, and other, non-pro-
cedure-related, clinical risk factors, such as recurrent my-
ocardial infarction and previous stent thrombosis. Fig. 1
shows a flowchart depicting the recommended duration of
DAPT after PCI for stable CAD, and ACS, from our per-
spective. Current evidence supports a DAPT duration for
up to 33 months. However, we believe that if a patient
has a high ischaemic risk, a patient should be treated with
dual antiplatelet therapy for as long as the bleeding risk is
acceptable; in some patients this could mean lifelong treat-
ment. Since risk stratification is a dynamic process, cardi-
ologists should perform periodical reassessment of a pa-
tient’s ischaemic and haemorrhagic risk. This requires rou-
tine, yearly outpatient visits including regular check-ups for
haemoglobin, thrombocytopenia, and creatinine clearance,
for as long as a patient is on DAPT. Finally, with regards
to the ischaemic risk, DAPT and its duration are just one
factor in the secondary prevention of cardiovascular events.
Other important include lipid-lowering treatment, treatment
of hypertension and diabetes, and other strategies for risk
factor modification and lifestyle changes such as diet, ex-
ercise and smoking cessation.
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